Sugi Predict

Sugi Predict / Compounds / SCHEMBL500787

SCHEMBL500787

SCHEMBL500787

CC(C)(C)OC(=O)N1C[C@H](CO)[C@@H](O)C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.59
▸ PDE4B Q07343 2/20 0.45
▸ USP2 O75604 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CHRM2 P08172 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ NAMPT P43490 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ RECQL P46063 1/20 0.38
▸ EPHX1 P07099 1/20 0.38
▸ DDB1 Q16531 1/20 0.37
▸ CRBN Q96SW2 1/20 0.37
▸ RORC P51449 1/20 0.36
▸ EPHX2 P34913 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10305448 1.00 NR1H2 (0.59) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL6505486 1.00 NR1H2 (0.59) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL500788 1.00 NR1H2 (0.59) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL4736582 1.00 NR1H2 (0.59) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL30721755 0.91 NR1H2 (0.65) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL1014216 0.91 NR1H2 (0.65) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL2930155 0.91 NR1H2 (0.65) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL2937360 0.91 NR1H2 (0.65) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL9972997 0.88 NR1H2 (0.53) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL19083300 0.88 NR1H2 (0.53) NR1H2PDE4BUSP2SMN1; SMN2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES CILAG AG (CH) 2024-05-30 — — US disclosed
EP-4284802-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Janssen Biotech, Inc. (US) 2023-12-06 — — EP disclosed
WO-2022165530-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES JANSSEN BIOTECH, INC. (US) 2022-08-04 — — WO disclosed
EP-3527554-A2 SALT AND POLYMORPHIC FORMS OF (3R,4S)-L-((4-AMINO-5H-PYRROLO[3,2-D]PYRIMIDIN-7-YL)METHYL)-4(METHYLTHIOMETHYL)PYRROLIDIN-3-OL(MTDIA) Victoria Link Limited (NZ) 2019-08-21 — — EP disclosed
EP-3527554-A2 SALT AND POLYMORPHIC FORMS OF (3R,4S)-L-((4-AMINO-5H-PYRROLO[3,2-D]PYRIMIDIN-7-YL)METHYL)-4(METHYLTHIOMETHYL)PYRROLIDIN-3-OL(MTDIA) Victoria Link Limited (NZ) 2019-08-21 — — EP disclosed
US-10227351-B2 Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-D]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA) VICTORIA LINK LIMITED (NZ) 2019-03-12 — — US disclosed
US-10227351-B2 Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-D]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA) VICTORIA LINK LIMITED (NZ) 2019-03-12 — — US disclosed
US-20180319803-A1 SALT AND POLYMORPHIC FORMS OF (3R,4S)-L-((4-AMINO-5H-PYRROLO[3,2,-D]PYRIMIDIN-7-YL)METHYL)-4(METHYLTHIOMETHYL)PYRODIN-3-OL(MTDIA) VICTORIA LINK LIMITED (NZ) 2018-11-08 — — US disclosed
US-9994574-B2 Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA) VICTORIA LINK LIMITED (NZ) 2018-06-12 — — US disclosed
US-9994574-B2 Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA) VICTORIA LINK LIMITED (NZ) 2018-06-12 — — US disclosed
US-20080280334-A1 Method for Preparing 3-Hydroxy-4-Hydroxymethyl-Pyrrolidine Compounds ALBERT EINSTEIN COLLEGE OF MEDICINE 2008-11-13 — — US disclosed
US-7230119-B2 Process for the preparation of substituted pyrrolidine derivatives and intermediates BIOCRYST PHARMACEUTICALS, INC. (US) 2007-06-12 — — US disclosed
US-7230119-B2 Process for the preparation of substituted pyrrolidine derivatives and intermediates BIOCRYST PHARMACEUTICALS, INC. (US) 2007-06-12 — — US disclosed
US-20060281779-A1 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2006-12-14 — — US disclosed
US-20060217551-A1 Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases INDUSTRIAL RESEARCH LIMITED (NZ) 2006-09-28 — — US disclosed
US-20060160765-A1 Inhibitors of nucleoside phosphorylases and nucleosidases BIOCRYST PHARMACEUTICALS, INC. 2006-07-20 — — US disclosed
EP-1666477-A1 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2006-06-07 — — EP disclosed
EP-1539783-A1 INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2005-06-15 — — EP disclosed
WO-2005033076-A1 METHOD FOR PREPARING 3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDINE COMPOUNDS INDUSTRIAL RESEARCH LIMITED (NZ) 2005-04-14 — — WO disclosed
WO-2004018496-A1 INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2004-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227351-B2 Salt and polymorphic forms of (3R,4S)-L-((4-amino-5H-pyrrolo[3,2,-D]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(MTDIA) MTAP, TPMT, TYMP NR1H2 4817/4885PDE4B 589/4885USP2 3965/4885
US-20180319803-A1 SALT AND POLYMORPHIC FORMS OF (3R,4S)-L-((4-AMINO-5H-PYRROLO[3,2,-D]PYRIMIDIN-7-YL)METHYL)-4(METHYLTHIOMETHYL)PYRODIN-3-OL(MTDIA) MTAP, TPMT, TYMP NR1H2 4817/4885PDE4B 589/4885USP2 3965/4885
US-20060281779-A1 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative RPS27L, RPS7, RPSA NR1H2 3791/4885PDE4B 1675/4885USP2 1469/4885
US-20080280334-A1 Method for Preparing 3-Hydroxy-4-Hydroxymethyl-Pyrrolidine Compounds HPD, DHPS, CYP3A5 NR1H2 1734/4885PDE4B 488/4885USP2 2201/4885
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES SIK2, SIK1, SGK2 NR1H2 1934/4885PDE4B 2506/4885USP2 2482/4885
US-20060160765-A1 Inhibitors of nucleoside phosphorylases and nucleosidases PNP, MTAP, TYMP NR1H2 4352/4885PDE4B 528/4885USP2 3991/4885
US-20060217551-A1 Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases PNP, MTAP, TYMP NR1H2 4417/4885PDE4B 432/4885USP2 3379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.